ALVAC-CEA vaccine

From Wikipedia, the free encyclopedia
Jump to: navigation, search

ALVAC-CEA vaccine is a cancer vaccine containing a canary pox virus (ALVAC) combined with the carcinoembryonic antigen (CEA) human gene.

A phase I trial in 118 patients showed safety in humans.[1]

References[edit]

External links[edit]

 This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".